A 52-week, Multicenter, Randomized, Double-blind Study of Subcutaneous Secukinumab to Demonstrate Efficacy as Assessed by Psoriasis Area and Severity Index at 16 Weeks of Treatment Compared to Ustekinumab and to Assess Long-term Safety, Tolerability and Efficacy in Subjects With Moderate to Severe Plaque Psoriasis (CLEAR)

Trial Profile

A 52-week, Multicenter, Randomized, Double-blind Study of Subcutaneous Secukinumab to Demonstrate Efficacy as Assessed by Psoriasis Area and Severity Index at 16 Weeks of Treatment Compared to Ustekinumab and to Assess Long-term Safety, Tolerability and Efficacy in Subjects With Moderate to Severe Plaque Psoriasis (CLEAR)

Completed
Phase of Trial: Phase III

Latest Information Update: 20 Feb 2018

At a glance

  • Drugs Secukinumab (Primary) ; Ustekinumab
  • Indications Plaque psoriasis
  • Focus Registrational; Therapeutic Use
  • Acronyms CLEAR
  • Sponsors Novartis; Novartis Pharmaceuticals
  • Most Recent Events

    • 05 Feb 2018 Results of pooled post hoc analysis of ERASURE, FIXTURE and CLEAR trials evaluating the efficacy and safety of secukinumab published in the Drugs and Aging
    • 12 Jan 2018 Results of post hoc analysis assessing direct and indirect (mediated) effects of secukinumab versus ustekinumab on quality of life, work productivity and activity impairment based on psoriasis severity and symptoms, were published in the British Journal of Dermatology.
    • 12 Oct 2017 Results of a post-hoc analysis assessing patient reported outcomes and cumulative clinical and patient-reported outcomes through week 52, published in the Journal of the American Academy of Dermatology
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top